CAR-T is a type of treatment in which a patient’s T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient’s blood. Then the gene for a special receptor that binds to a certain protein on the patient’s cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion. CAR T-cell therapy is used to treat certain blood cancers, and it is being studied in the treatment of other types of cancer. Also called chimeric antigen receptor T-cell therapy.
DelveInsight’s, “CAR-T Pipeline Insights, 2021,” report provides comprehensive insights about 250+ companies and 250+ pipeline drugs in CAR-T pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Get free sample report: https://www.delveinsight.com/sample-request/car-t-pipeline-insight
Some of the CAR-T Companies:
Some of the CAR-T Therapies:
Table of Contents:
Introduction
Executive Summary
CAR-T: Overview
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
CAR-T – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• CAR-T companies’ collaborations, Licensing, Acquisition -Deal Value Trends
CAR-T Collaboration Deals
Late Stage Products (Phase II)
JNJ-68284528: Janssen Research & Development, LLC
Mid Stage Products (Phase II)
LCAR-B38M CAR-T Cell: Nanjing Legend Biotech Co.
CD30.CAR-T: Tessa Therapeutics
Early Stage Products (Phase I)
IM21 CAR-T cells: Beijing Immunochina Medical Science & Technology Co., Ltd.
Pre-clinical and Discovery Stage Products
Research programme: CAR-T cell therapy – Endocyte/Seattle Childrens Research Institute
Research programme: chimeric antigen receptor T cell therapies – CRISPR Therapeutics
Inactive Products
Comparative Analysis
CAR-T- Market Drivers and Barriers
Appendix
About DelveInsight DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/car-t-pipeline-insight